Ascentage Pharma Group International (HKG:6855)
Hong Kong · Delayed Price · Currency is HKD 45.26
+1.72 (3.95%)
Mar 6, 2026, 4:08 PM HKT
Ascentage Pharma Group International Employees
Ascentage Pharma Group International had 605 employees as of June 30, 2025. The number of employees increased by 38 or 6.70% since the number was reported on December 31, 2024.
Employees
605
Change
38
Growth
6.70%
Revenue / Employee
707.46K HKD
Profits / Employee
-2.10M HKD
Market Cap
16.66B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 605 | 38 | 6.70% |
| Dec 31, 2024 | 567 | -16 | -2.74% |
| Dec 31, 2023 | 583 | 3 | 0.52% |
| Dec 31, 2022 | 580 | -33 | -5.38% |
| Dec 31, 2021 | 613 | 180 | 41.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 5,769 |
| Shanghai Haohai Biological Technology | 2,156 |
| Zai Lab | 1,869 |
| Keymed Biosciences | 1,469 |
| InnoCare Pharma | 1,176 |
| Everest Medicines | 722 |
| Ascletis Pharma | 208 |
| PegBio | 58 |
Ascentage Pharma Group International News
- 3 days ago - Ascentage Pharma Group International is Now Oversold (AAPG) - Nasdaq
- 22 days ago - Ascentage Pharma Group International (AAPG) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 4 weeks ago - Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - GlobeNewsWire
- 6 weeks ago - Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 7 weeks ago - Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment - Benzinga
- 3 months ago - ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP - GlobeNewsWire